fbpB Antibody

What is fbpB and why is it significant in mycobacterial research?

fbpB is a gene that encodes Ag85B (Antigen 85B), a protein belonging to the Antigen 85 complex found in mycobacteria. It functions as a diacylglycerol acyltransferase/mycolyltransferase and plays a crucial role in cell wall biosynthesis . Its significance in research stems from multiple factors: first, it's highly immunogenic, making it a key target for studying host immune responses; second, its expression patterns change during different phases of infection, providing insights into bacterial adaptation mechanisms; and third, it's involved in the pathogenesis of mycobacterial diseases, particularly tuberculosis . Understanding fbpB expression and function helps researchers investigate mycobacterial virulence factors and develop potential therapeutic and diagnostic approaches.

What types of fbpB antibodies are available for research applications?

Researchers can access several types of fbpB antibodies, with polyclonal antibodies being the most commonly documented. For instance, the FBPB Polyclonal Antibody (PACO61814) is produced in rabbits and has been validated for Western blot and ELISA applications . These antibodies are typically raised against recombinant Ag85B protein fragments, such as the 41-325AA region of Mycobacterium kansasii Ag85B . Both conjugated and non-conjugated formats exist, with non-conjugated being more versatile for various detection methods. While polyclonal antibodies offer broad epitope recognition, monoclonal antibodies provide more specific targeting of particular epitopes on the Ag85B protein, though these weren't specifically mentioned in the search results.

What are the standard applications for fbpB antibodies in mycobacterial research?

fbpB antibodies serve multiple critical functions in mycobacterial research:

• Protein Detection: Western blotting using fbpB antibodies can detect Ag85B expression in bacterial samples with recommended dilutions of 1:500-1:5000 .

• Quantitative Analysis: ELISA applications allow researchers to quantify Ag85B levels in various samples using dilutions ranging from 1:2000-1:10000 .

• Immunological Studies: These antibodies enable investigation of T-cell responses to Ag85B, helping researchers understand host-pathogen interactions during infection .

• Bacterial Phenotyping: They allow detection of differential expression of fbpB/Ag85B during various phases of infection or under different growth conditions .

The observed molecular weight for Ag85B detection is approximately 50 kDa, which matches the predicted band size in Western blot applications .

How does fbpB gene expression change during the course of M. tuberculosis infection, and how can antibodies help track this?

M. tuberculosis demonstrates strategic regulation of fbpB expression throughout infection stages. During early infection, fbpB is highly expressed, but levels decrease dramatically (approximately 100-fold) as infection transitions to the chronic phase . This downregulation appears to be a bacterial immune evasion mechanism that reduces T-cell activation.

Researchers can track these expression changes using fbpB antibodies in combination with techniques such as:

• Immunohistochemistry on infected tissue samples collected at different time points

• Flow cytometry to correlate bacterial Ag85B expression with immune cell activation

• Western blot analysis of bacterial lysates from different infection stages

• Correlative studies combining RT-qPCR data measuring fbpB mRNA with protein detection using antibodies

These approaches reveal important insights about bacterial adaptation mechanisms. For example, research has demonstrated that this downregulation correlates directly with decreased activation of Ag85B-specific CD4+ effector T cells, supporting the hypothesis that fbpB regulation is a deliberate immune evasion strategy .

What are the technical challenges in producing and validating fbpB antibodies for tuberculosis research?

Producing reliable fbpB antibodies presents several technical challenges:

• Protein Structure Considerations: Ag85B's structural similarity to other Ag85 complex proteins (Ag85A and Ag85C) can lead to cross-reactivity issues. Antibodies must be validated against these similar proteins to ensure specificity.

• Expression Systems: Recombinant Ag85B production requires careful selection of expression systems. While the documented antibody uses recombinant Mycobacterium kansasii Ag85B protein (41-325AA) , researchers must consider whether their specific mycobacterial species of interest may have structural variations.

• Validation Complexity: Proper validation requires:

  • Western blot confirmation using both recombinant protein and native protein from mycobacterial lysates

  • Testing against multiple mycobacterial species if cross-species reactivity is desired

  • Specificity testing against other Ag85 complex members

• Storage and Stability: Antibody preparations require specific storage conditions (typically in 50% glycerol with 0.03% Proclin 300 preservative in 0.01M PBS, pH 7.4) to maintain stability and activity over time.

Cross-validation using complementary techniques (qPCR for mRNA levels alongside protein detection) helps establish antibody reliability for measuring biological changes in Ag85B expression during infection or experimental manipulation .

How can fbpB antibodies be used to investigate immune evasion mechanisms in mycobacterial infections?

fbpB antibodies provide valuable tools for investigating immune evasion strategies employed by mycobacteria:

• Temporal Expression Mapping: By detecting Ag85B protein levels at different infection stages, researchers can correlate protein expression with T-cell activation patterns. Studies show that downregulation of fbpB corresponds directly to reduced activation of Ag85B-specific CD4+ T cells .

• Comparative Studies with Engineered Strains: Researchers can use fbpB antibodies to confirm protein expression in modified bacterial strains engineered to maintain fbpB expression, such as the CPE85B strain which expresses fbpB under the control of the hspX promoter . Western blot analysis can confirm sustained Ag85B production throughout infection stages.

• Antigen Presentation Studies: fbpB antibodies can be used in co-culture systems with infected dendritic cells and T cells to measure how Ag85B availability impacts antigen presentation and subsequent T-cell activation. This helps quantify the relationship between antigen levels and immune response intensity .

• In vivo Tracking: Combined with fluorescent secondary antibodies, fbpB antibodies can be used to track antigen availability in tissue sections from infected animal models, correlating bacterial protein expression with local immune response patterns.

This research approach has revealed that bacterial downregulation of fbpB represents a significant immune evasion mechanism that limits effector T-cell activation during chronic infection phases .

What are the optimal protocols for using fbpB antibodies in Western blot applications?

For optimal Western blot results with fbpB antibodies, researchers should consider this detailed protocol:

Sample Preparation:

• Prepare mycobacterial lysates using appropriate biosafety measures

• Include recombinant Ag85B protein as a positive control

• Load 20-30 μg of total protein per lane

Procedure:

• Separate proteins using 10-12% SDS-PAGE gels

• Transfer to PVDF or nitrocellulose membrane (0.45 μm pore size recommended)

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary fbpB antibody at 1:500-1:5000 dilution (optimal dilution should be determined empirically for each lot)

• Wash 3-4 times with TBST

• Incubate with secondary antibody (anti-rabbit IgG) at 1:50000 dilution

• Develop using chemiluminescent substrate

Expected Results:

• Predicted band size: 50 kDa

• Observed band size: 50 kDa

Troubleshooting Tips:

• If background is high, increase antibody dilution or blocking time

• For weak signals, reduce antibody dilution or increase exposure time

• For multiple bands, increase washing steps or antibody specificity testing

How should researchers design experiments to study the relationship between fbpB expression and T-cell activation?

Based on published research methodologies, an optimal experimental design would include:

In Vitro Studies:

• Dendritic Cell Infection Model:

  • Infect bone marrow-derived dendritic cells (BMDCs) with wild-type and modified bacterial strains (e.g., H37Rv vs. CPE85B)

  • Confirm bacterial load equivalence by CFU plating

  • Verify differential Ag85B expression using fbpB antibodies in Western blot

  • Co-culture infected BMDCs with Ag85B-specific T cells (e.g., P25TCR-tg CD4+ T cells)

  • Measure T-cell activation by IFN-γ production using ELISA or intracellular cytokine staining

• Analysis Parameters:

  • Test multiple APC:T cell ratios (typically 1:1, 1:5, 1:10)

  • Include appropriate controls (uninfected DCs, irrelevant antigen)

  • Conduct time-course experiments to capture temporal dynamics

In Vivo Studies:

• Adoptive Transfer Model:

  • Transfer labeled Ag85B-specific T cells (e.g., CFSE-labeled P25TCR-tg CD4+ cells) into infected animals

  • Collect lung and lymph node samples at different infection time points

  • Analyze T-cell proliferation by flow cytometry

  • Measure cytokine production by intracellular staining

  • Correlate with bacterial fbpB expression using RT-qPCR and protein detection with fbpB antibodies

• Data Correlation:

  • Plot the percentage of activated T cells against fbpB expression levels to establish quantitative relationships

  • Compare wild-type infection with modified strains expressing constant fbpB levels

This approach allows researchers to establish causal relationships between antigen availability and T-cell response magnitude while controlling for other variables.

What controls should be included when using fbpB antibodies in immunological studies?

A comprehensive set of controls is essential for reliable interpretation of experiments using fbpB antibodies:

Antibody Validation Controls:

• Positive Control: Recombinant Ag85B protein at known concentration

• Negative Controls:

  • Lysates from fbpB knockout strains

  • Irrelevant protein with similar molecular weight

  • Pre-immune serum at same dilution as primary antibody

• Specificity Controls:

  • Other Ag85 complex proteins (Ag85A, Ag85C) to assess cross-reactivity

  • Multiple mycobacterial species to determine species specificity

Experimental Controls:

• Loading Control: Antibody against constitutively expressed mycobacterial protein

• Technique Controls:

  • Secondary antibody only (no primary) to assess non-specific binding

  • Technical replicates to ensure reproducibility

  • Biological replicates (minimum n=3) for statistical validity

Specialized Controls for T-cell Studies:

• T-cell Specificity Controls:

  • T cells specific for irrelevant mycobacterial antigens

  • Polyclonal T-cell populations to compare with antigen-specific responses

• Antigen Presentation Controls:

  • Exogenous Ag85B peptide addition to ensure T-cell functionality

  • APCs infected with bacterial strains expressing varying levels of fbpB

Using this comprehensive control strategy allows for accurate interpretation of results while minimizing false positives and negatives in fbpB antibody-based research.

How can fbpB antibodies be used to evaluate novel tuberculosis vaccine candidates?

fbpB antibodies provide valuable tools for vaccine development research through multiple approaches:

• Antigen Expression Verification:

  • For vaccine candidates incorporating Ag85B, antibodies can verify antigen expression levels and stability

  • Western blot analysis can confirm correct protein size and integrity

  • ELISA can quantify antigen concentration in vaccine formulations

• Immune Response Characterization:

  • Following vaccination, researchers can use Ag85B-stimulated cell cultures to assess:

    • Antigen presentation efficiency by APCs isolated from vaccinated subjects

    • T-cell activation patterns, comparing these with responses during natural infection

    • Correlation between antibody responses to Ag85B and protective immunity

• Mechanistic Studies:

  • Comparing wild-type M. tuberculosis with strains engineered for constitutive fbpB expression (like CPE85B) provides insights into how antigen persistence affects immunity

  • Researchers can determine whether maintaining high Ag85B levels, as in the CPE85B strain which shows reduced bacterial burden in mouse models , represents a viable vaccine strategy

• Correlates of Protection:

  • Using fbpB antibodies to measure antigen-specific memory B cells and antibody production

  • Establishing correlations between Ag85B-specific immune responses and protection against challenge

This approach has highlighted that sustained antigen availability might improve vaccine efficacy, as evidenced by the improved control of infection seen with the CPE85B strain that maintains high fbpB expression throughout infection .

What are the implications of fbpB downregulation for developing immunodiagnostic tools for tuberculosis?

The dynamic regulation of fbpB expression during tuberculosis infection has significant implications for diagnostics:

• Diagnostic Timing Considerations:

  • fbpB expression decreases approximately 100-fold during progression to chronic infection

  • Early-stage diagnostics targeting Ag85B may be more sensitive than those for chronic stage detection

  • This temporal pattern must be considered when interpreting negative results

• Antibody Selection Strategy:

  • Diagnostic developers should select epitopes on Ag85B that remain accessible even during downregulation

  • Polyclonal antibody preparations may offer broader detection capability across infection stages

• Multi-target Approach:

  • The variable expression of fbpB suggests that robust diagnostics should include multiple mycobacterial targets

  • Combining markers expressed during different infection phases would improve sensitivity

• Application to Latent TB Detection:

  • The decreased fbpB expression during chronic infection suggests that Ag85B-based diagnostics might have limitations for detecting latent TB

  • Alternative markers or highly sensitive detection methods would be necessary for latent infection

These insights highlight why current TB diagnostics often employ multiple antigens and why understanding expression kinetics is crucial for diagnostic development and interpretation.

What are the most significant recent advances in fbpB antibody applications for mycobacterial research?

Recent advances in fbpB antibody applications have substantially expanded our understanding of mycobacterial pathogenesis and immune evasion:

• Immune Evasion Mechanism Characterization:

  • The discovery that M. tuberculosis deliberately downregulates fbpB expression to limit CD4+ T-cell activation represents a significant breakthrough in understanding bacterial persistence mechanisms

  • This finding helps explain why otherwise robust T-cell responses fail to clear infection

• Engineered Bacterial Strains:

  • The development of strains with constitutive fbpB expression, such as CPE85B with the hspX promoter driving fbpB expression , has provided valuable tools for investigating:

    • The causal relationship between antigen availability and T-cell activation

    • How sustained antigen presentation affects infection outcomes

    • Potential new vaccine development strategies

• Integration with Advanced Technologies:

  • Combining fbpB antibody detection with techniques like single-cell RNA sequencing allows for correlation between bacterial gene expression and host cell responses at unprecedented resolution

  • This integration facilitates understanding of the heterogeneity in both bacterial populations and host responses

• Therapeutic Implications:

  • The finding that forced fbpB expression impairs bacterial persistence during chronic infection suggests that targeting mechanisms of antigen downregulation could potentially enhance immune control of infection

These advances collectively point to new research directions focused on overcoming bacterial immune evasion strategies for improved tuberculosis control.

How does the knowledge of fbpB expression dynamics inform future research directions?

The documented pattern of fbpB downregulation during infection progression opens several promising research avenues:

• Bacterial Regulation Mechanisms:

  • Investigation into the molecular mechanisms controlling fbpB expression

  • Identification of potential drug targets that could prevent downregulation

  • Exploration of other antigens similarly regulated during infection progression

• Host-Pathogen Interface:

  • Detailed mapping of how changing antigen levels affect different T-cell populations

  • Investigation of memory T-cell maintenance in environments with fluctuating antigen levels

  • Understanding how antigen expression patterns shape immune repertoire development

• Therapeutic Strategies:

  • Development of approaches to maintain antigen presentation despite bacterial downregulation

  • Creation of modified vaccine strains that express key antigens throughout infection

  • Testing whether combined targeting of antigens expressed at different infection stages improves outcomes

• Translational Applications:

  • Designing diagnostic algorithms that account for temporal expression patterns

  • Developing therapeutic vaccines that boost responses to antigens expressed during chronic infection

  • Creating host-directed therapies that enhance recognition of low-abundance antigens